Serum-based tests will be designed to help decipher response to various cancer treatments.


Serametrix is joining forces with the Ludwig Institute for Cancer Research (LICR) to develop and commercialize tests that predict and monitor drug response in cancer patients. The serum-based tests are expected to be of value to clinicians as well as drug developers.

The agreement combines LICR’s discoveries in tumor immunology with Serametrix’ technologies and commercial capabilities. The institute’s flagship antigen, NY-ESO-1, has been licensed to Serametrix as part of this agreement. It has reportedly already shown potential as a predictor of drug response. Serametrix will add to its current array-based services a serum-profiling service dedicated solely to NY-ESO-1 antibody detection.

As part of the deal LICR will take an equity stake in Serametrix. Additionally, the director of LICR’s New York branch, Lloyd Old, M.D., was appointed chairman of Serametrix’ scientific advisory board.

 








This site uses Akismet to reduce spam. Learn how your comment data is processed.